Ideaya Biosciences enters option, license agreement for B7H3/PTK7 BsADC program

Ideaya Biosciences announced that it has entered into an option and license agreement for a B7H3/PTK7 BsADC program with Biocytogen Pharmaceuticals. The agreement grants Ideaya an option for an exclusive worldwide license from Biocytogen for a potential first-in-class B7H3/PTK7 topo-I-payload BsADC program. B7H3/PTK7 has been found to be co-expressed in multiple solid tumor types, including double-digit percent prevalence in lung, colorectal, and head and neck cancers, among others. Under the terms of the agreement, Biocytogen will receive an upfront fee and upon an option exercise by Ideaya, be entitled to receive an option exercise fee, development and regulatory milestones and commercial milestone payments, as well as single-digit royalties on net sales. Total potential upfront, option exercise and milestone payments equal an aggregate of $406.5M, including development and regulatory milestones of $100M. Based on preclinical data, the potential first-in-class B7H3/PTK7 topoisomerase-I-inhibitor-payload BsADC program has the potential to be developed as a monotherapy agent and used in combination with multiple programs in IDEAYA’s pipeline targeting DDR-based therapies, including PARG inhibitor IDE161. A development candidate nomination for the B7H3/PTK7 topoisomerase-I-inhibitor payload BsADC program is targeted for the second half of 2024.